Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INM 
InMed Pharmaceuticals Inc (INM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: INM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.77% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.08M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) - | Beta 0.28 | 52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 |
52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -168.9% | Operating Margin (TTM) -167.67% |
Management Effectiveness
Return on Assets (TTM) -44.64% | Return on Equity (TTM) -91.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 297344 | Price to Sales(TTM) 0.83 |
Enterprise Value 297344 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 1 | Shares Outstanding 1207190 | Shares Floating 1205387 |
Shares Outstanding 1207190 | Shares Floating 1205387 | ||
Percent Insiders 1.45 | Percent Institutions 10.18 |
Upturn AI SWOT
InMed Pharmaceuticals Inc
Company Overview
History and Background
InMed Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of novel therapeutics for diseases with high unmet medical needs and cannabinoid-based pharmaceutical products. Founded in 2014, InMed has focused on developing innovative therapies through its IntegraSyn platform and drug delivery technologies.
Core Business Areas
- Drug Development: Developing cannabinoid-based pharmaceutical candidates for various diseases, including dermatological and ophthalmic conditions.
- IntegraSyn Platform: Utilizing a proprietary platform to produce pharmaceutical-grade cannabinoids efficiently and sustainably.
Leadership and Structure
The company is led by a team of experienced executives in the pharmaceutical and biotechnology industries. It operates with a research and development-focused organizational structure.
Top Products and Market Share
Key Offerings
- INM-715: A cannabinoid analog under development for the treatment of glaucoma. Clinical trials are ongoing. Market share data is not yet available as it's still in development. Competitors include companies developing other glaucoma medications such as Novartis (NOVN), Allergan (ABBV), and Aerie Pharmaceuticals (ARIE).
- INM-901: A cannabinoid analog formulation in development for epidermolysis bullosa (EB). Clinical trials are ongoing. Market share data is not yet available as it's still in development. Competitors include companies developing treatments for EB such as Amicus Therapeutics (FOLD) and Castle Creek Biosciences.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The market for cannabinoid-based therapeutics is growing, driven by increasing acceptance of cannabis and its potential medical benefits.
Positioning
InMed aims to establish itself as a leader in the development of cannabinoid-based therapies through its IntegraSyn platform and focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for targeted diseases (e.g., glaucoma, EB) is substantial, potentially reaching billions of dollars. InMed's positioning depends on the clinical success and regulatory approval of its drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary IntegraSyn platform
- Focus on unmet medical needs
- Experienced management team
- Pipeline of cannabinoid-based therapeutics
Weaknesses
- Limited financial resources
- Early stage of development
- Reliance on successful clinical trials
- Dependence on regulatory approvals
Opportunities
- Growing market for cannabinoid-based therapeutics
- Potential for partnerships and collaborations
- Expansion of pipeline into new indications
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and changing regulations
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- GWPH
- ABBV
- NOVN
Competitive Landscape
InMed faces intense competition from established pharmaceutical companies with greater resources and expertise. Its competitive advantage lies in its proprietary IntegraSyn platform and focus on cannabinoid-based therapies for specific indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in preclinical and clinical development programs.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst projections vary depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing clinical trials for INM-715 and INM-901 and exploring new applications for its IntegraSyn platform.
Summary
InMed Pharmaceuticals Inc. is a high-risk, high-reward biopharmaceutical company focused on cannabinoid-based therapies. The company's strength lies in its IntegraSyn platform and pipeline. However, it faces significant challenges related to funding, clinical trial success, and regulatory approvals. The company's success hinges on positive data from its ongoing clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- InMed Pharmaceuticals Inc. website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may be subject to change. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-11-12 | President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.inmedpharma.com |
Full time employees 13 | Website https://www.inmedpharma.com | ||
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.